Posted by Michael Wonder on 26 Sep 2023
Sandoz receives European Commission approval for Tyruko (natalizumab), first and only biosimilar for multiple sclerosis in Europe
26 September 2023 - Decision based on evidence from extensive analytical characterisation demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies.
Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Commission granted marketing authorisation for the first and only biosimilar Tyruko (natalizumab), developed by Polpharma Biologics.
